Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.

Front Oncol · 2020 · PMC7693629 · PMID 33304851

Europe PMC DOI

hedged sentence

0.3440

closest p · 6.9× alpha

0.3440

boldest claim

The sentences

did not reach statistical significancep = 0.344not close (p > 0.1)

And in BRCA mutant subgroup of BrighTNess trial, 92 TNBC patients with BRCA mutation was included and platinum based regimen showed the trend with increasing pCR rate (platinum group: 56.5%, control group: 40.9%), however, it did not reach statistical significance (p = 0.344) ( 10 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.